Table 6 Models for overall grade ≥ 3 toxicity in gastric cancer patients treated with platinum/fluoropyridines -based chemotherapy using multivariate analysis
| Â | Model 1 | Model 2 | Model 3 | Model 4 | ||||
|---|---|---|---|---|---|---|---|---|
Characteristics | OR [95% CI] | p-value | OR [95% CI] | p-value | OR [95% CI] | p-value | OR [95% CI] | p-value |
Age (above median) | 1.71 (0.67–4.48) | 0.25 | – | – | 2.33 (0.81–7.15) | 0.12 | 2.24 (0.77–6.96) | 0.14 |
Sex (Female) | 1.83 (0.68–5.05) | 0.23 | – | – | 2.12 (0.68–7.01) | 0.19 | 2.18 (0.70–7.29) | 0.18 |
CMT peri-op (Yes) | 2.66 (1.00–7.35) | 0.05 | – | – | 2.26 (0.73–7.28) | 0.15 | 3.01 (0.94–10.31) | 0.06 |
5-FU based (Yes) | 1.73 (0.55–6.10) | 0.35 | – | – | 2.03 (0.58–8.06) | 0.28 | 1.65 (0.46–6.50) | 0.44 |
SNPs | ||||||||
 ERCC2 (dom. TG/GG) | – | – | 1.56 (0.57–4.31) | 0.37 | 1.24 (0.41–3.63) | 0.68 | – | – |
 DPYD (CT) (rs2297595) | – | – | 1.56 (0.26–9.95) | 0.61 | 1.88 (0.25–14.77) | 0.52 | – | – |
 DPYD (dom. TT) (rs1801159) | – | – | 2.32 (0.89–6.24) | 0.08 | 2.53 (0.91–7.44) | 0.07 | – | – |
 DPYD (dom. AG/GG) (rs1801265) | – | – | 3.74 (1.46–10.08) | 0.006 | 4.55 (1.64–13.79) | 0.004 | – | – |
 GSTP1 (dom. AG/GG) (rs1695) | – | – | 0.71 (0.26–1.90) | 0.50 | 0.59 (0.19–1.74) | 0.34 | – | – |
SNPs combination | ||||||||
 DPYD dom. + ABCC2 dom. (rs1801265 + rs717620) | – | – | – | – |  |  | – | – |
 AA + CT/TT | – | – | – | – |  |  | 1.45 (0.18–8.68) | 0.68 |
 AG/GG + CC | – | – | – | – |  |  | 4.33 (1.43–14.68) | 0.012 |
 AG/GG + CT/TT | – | – | – | – |  |  | 18.00 (1.66–439) | 0.027 |
 DPYD (dom. TT) (rs1801159) | – | – | – | – |  |  | 2.37 (0.87–6.75) | 0.094 |
| Â | Model 1 | Model 2 | Model 3 | Model 4 | ||||
Pseudo R2 | 0.07 | 0.15 | 0.21 | 0.21 | ||||